Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer

Diego G. Dupouy1, Ata Tuna Ciftlik1,3, Maryse Fiche2, Déborah Heintze1,3, Bettina Bisig2, Laurence de Leval2 & Martin A. M. Gijs2

Chromogenic immunohistochemistry (IHC) is omnipresent in cancer diagnosis, but has also been criticized for its technical limit in quantifying the level of protein expression on tissue sections, thus potentially masking clinically relevant data. Shifting from qualitative to quantitative, immunofluorescence (IF) has recently gained attention, yet the question of how precisely IF can quantify antigen expression remains unanswered, regarding in particular its technical limitations and applicability to multiple markers. Here we introduce microfluidic precision IF, which accurately quantifies the target expression level in a continuous scale based on microfluidic IF staining of standard tissue sections and low-complexity automated image analysis. We show that the level of HER2 protein expression, as continuously quantified using microfluidic precision IF in 25 breast cancer cases, including several cases with equivocal IHC result, can predict the number of HER2 gene copies as assessed by fluorescence in situ hybridization (FISH). Finally, we demonstrate that the working principle of this technology is not restricted to HER2 but can be extended to other biomarkers. We anticipate that our method has the potential of providing automated, fast and high-quality quantitative in situ biomarker data using low-cost immunofluorescence assays, as increasingly required in the era of individually tailored cancer therapy.

Continuous quantification of HER2 protein expression in breast cancer has long been the missing link between methods analyzing nucleic acids and conventional IHC. The majority of IHC tests currently used in clinical diagnosis cannot quantify the antigen (Ag) expression but rather perform a binary or semi-quantitative assessment as interpreted by the pathologist4. An example of such semi-quantitative tests is the assessment of HER2 protein expression level in breast cancer, for which the scoring can have four different levels: 0, 1+, 2+ or 3+. This non-continuous assessment results in a loss of information regarding the Ag expression level6,7. Comparison

1Laboratory of Microsystems, Ecole Polytechnique Fédérale de Lausanne, CH-1015, Switzerland. 2Institute of Pathology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011 Lausanne, Switzerland. 3Lunaphore Technologies SA, EPFL Innovation Park—Building C, CH-1015, Lausanne, Switzerland. Correspondence and requests for materials should be addressed to M.A.M.G. (email: martin.gijs@epfl.ch)
studies between IHC and FISH methods for HER2 have been widely performed in clinical research. Yet, if a routine method that precisely quantifies Ag expression in tissues while preserving the morphology could be established, not only would this reduce the requirement for expensive complementary gene analysis but also the precision of diagnosis, prognosis and the success of targeted therapies, in clinical trials and routine patient care.

In this context, as clinical pathology moves from qualitative to quantitative, immunofluorescence (IF) is gaining relevance in the research settings and laboratory-developed tests, mainly due to its increased capacity to measure the signal intensity of one or more biomarkers as compared to traditional chromogenic techniques. Several image processing techniques that quantify the extent of IF signal have already been reported in the literature. However, there is little or no evidence suggesting that the IF signal per se can be used to precisely quantify Ag expression amount on tissue sections. Indeed, due to the kinetics of Ag-antibody (Ab) binding, a 2-step IF delivery and washing of the reagents over a large surface is increasingly required for personalized cancer therapy.

We have recently introduced a microfluidic tool, called “Microfluidic Tissue Processor” (MTP) that increased the accuracy of semi-quantitative IF biomarker scoring in histopathological tissue sections. However, it just provided a better semi-quantitative scoring, and the use of this technology still did not show the quantification of the biomarker expression. Yet, this technology has a high potential to be a starting point in reaching continuous quantitative IF. Here, we introduce microfluidic precision IF, a method that precisely quantifies the target Ag expression in a continuous scale based on double staining of standard tissue sections with MTP and low-complexity automated image analysis. In the following, we selected 25 invasive breast carcinoma cases whose HER2 biomarker expression ranged across a large range of values known by routine diagnostics, as assessed by the two conventional methods used (i.e.: IHC and FISH), and for which several cases presented equivocal results. Using these cases, we show that, continuous quantification of HER2 protein expression by microfluidic precision immunofluorescence, one can estimate the number of copies of the coding gene, as assessed by FISH. Later, in a proof-of-concept experiment, we prove that the MTP fine-tunes immunoreactions on the tissue surface in a way that allows an IF staining to establish a linearly proportional relationship between the IF signal intensity and its Ag expression level. Therefore, we propose that the working principle is not restricted to the above cases, and in principle, can be extended to all biomarkers. We anticipate that our method has the potential to provide automated and precise continuous quantitative in situ biomarker data using low-cost immunofluorescence assays, as increasingly required for personalized cancer therapy.

Results
Continuous signal quantification of double IF staining using microfluidic precision immunofluorescence. For this proof-of-concept study, we used the MTP to perform IF staining assays on formalin-fixed paraffin-embedded (FFPE) sections of surgically resected human invasive breast carcinoma samples (Fig. 1A), retrieved from the archives of the Institute of Pathology at the University Hospital of Lausanne (Switzerland). By clamping the MTP half-chamber with the tissue slide (Fig. 1B), a shallow flow chamber with a height of 100 μm is formed, which constitutes a critical parameter of the working principle of the device, allowing fast and uniform delivery and washing of the reagents over a large surface (16 x 16 mm²) of tissue section. The chosen microfluidic architecture allows distributing the bioreagents uniformly within the chamber. To minimize variations in the exposure time of tissue sections to the bioreagents, the transport of the latter should rely minimally on diffusion within in-plane directions. To address this problem, we designed a distributed microfluidic channel network that permitted homogeneous flow throughout the entire chamber and assured that convection was the dominant mechanism for the in-plane bioreagent transport.

This resulted in an IF signal that was more proportional to the Ag concentration than what could be obtained by traditional IHC methods. The samples were first incubated with primary antibodies for HER2 and cytokeratin (CK), in a sequential manner. CK constitutes a marker for epithelial cells and it has been widely used in carcinomas to distinguish epithelia from stroma. Furthermore, CK-based normalization has proven to be a useful technique to increase accuracy in the quantification of HER2, by compensating for variations in the staining quality of the samples. In a second step, two fluorescently labeled secondary antibodies were sequentially delivered into the chamber, first for HER2 and then for CK detection. Finally the slides were washed with deionized water and cover-slipped using a solution containing 4′6-diamidino-2-phenylindole (DAPI) for nuclear counterstaining. After the staining process, the slides were automatically tile-by-tile scanned to obtain a mosaic image in three fluorescent channels, corresponding to the signals of DAPI, CK and HER2, respectively (Fig. 1C,D). Each tile from the resulting mosaic images was then analyzed by running a custom-made image-processing algorithm that identified locations of CK expression and created a region of interest to limit the interrogation of the HER2 signal to epithelial areas only. Similarly, the information from the DAPI channel was used to remove the nuclei from the interrogation zones, as the HER2 and CK markers of interest are not expressed in the nuclei.

Signal quantification data lead to distinct scatter plot signatures. As a result of the image-processing algorithm, 2D scatter plots were obtained, in which the averaged HER2 and CK signals per tile were represented as points. Figure 1E is an example of such scatter plot, in which an IHC HER2 2+ (equivocal) case is compared to a 3+ and a 0 case, the latter two being used as positive and negative controls, respectively. The data
from each scatter plot were subsequently processed to provide statistical indicators of HER2 expression, which finally resulted in the ‘MTP-score’ of our analysis (see further).

**Scatter plot signatures of HER2 protein expression in 25 breast cancer cases obtained by microfluidic precision IF, and their corresponding HER2 copy number as obtained by routine FISH.** We selected 25 invasive breast carcinoma cases, for which routine FISH analysis gave a wide range of HER2 gene copy numbers ($N_{\text{FISH}}$) ranging from 1.9 to 15 (see Table S1). IHC results were equivocal in several cases out of this series. Table S1 of the Supplementary Information shows the classification of IHC results for these 25 cases following the 2013 ASCO/CAP interpretation guidelines by two blinded experienced pathologists (M.F. and B.B.). By routine $N_{\text{FISH}}$ FISH analysis, based on the $N_{\text{FISH}}$ values, 10 cases out of the 25 were classified as negative ($N_{\text{FISH}} < 4$), 9 cases as positive ($N_{\text{FISH}} \geq 6$), and 6 cases as equivocal ($4 \leq N_{\text{FISH}} < 6$) (Neg, Pos, and Equ, respectively, in Fig. 2). Although the 2013 ASCO/CAP guidelines for HER2 status classification also takes into account the HER2/CEP17 ratio, we decided for the purpose of this study to focus on the correlation between HER2 protein expression and $N_{\text{FISH}}$.

For the MTP analysis, we grouped the 25 cases into 5 batches and processed all samples in a batch sequentially in one experimental run. We used an automated algorithm to define the areas that had epithelial cells and were to be interrogated for the presence of a HER2 signal, from which we obtained the average CK and HER2 signal for each tile of the mosaic image, resulting in the scatter plots of Fig. 2. From a statistical analysis of the latter, we calculated an MTP-score for each sample that clearly correlated with the $N_{\text{FISH}}$ values obtained from routine analysis (see further). At first sight already, the scatter plots of Fig. 2 show that the samples assigned a low $N_{\text{FISH}}$ value ($<\sim 3$) have a linear correlation of HER2 with CK, while for $N_{\text{FISH}} > \sim 5$, HER2 values get systematically higher and more dispersed.

**Automated comparison of a scatter plot to those of the control cases can estimate the HER2 gene copy number.** To exploit the scatter plot data of Fig. 2, we implemented a data processing algorithm that compares the scatter plot of a case under interrogation to those obtained from absolute negative and positive control cases. This algorithm starts by calculating the ratio between HER2 and CK signals on a tile-by-tile basis. The thus obtained data array is then plotted as a histogram, representing the frequency of occurrence of a given HER2/CK ratio normalized to the number of tiles. Figure 3 shows as examples the histograms obtained for five patients, whom prior routine analysis attributed the following IHC scores: 3+ (green), 2+ (blue) and 0 (red), and three cases
Figure 2. Scatter plot signatures obtained by MTP IF and the corresponding HER2 gene copy number for 25 invasive breast carcinoma cases. The listed values for the cell-averaged HER2 gene copy number ($N_{\text{FISH}}$) were obtained from FISH routine analysis. The HER2 status classification (Class.) by the pathologist is also given, based on $N_{\text{FISH}}$ as follows: $N_{\text{FISH}} < 4$: Negative; $4 \leq N_{\text{FISH}} < 6$: Equivocal; $N_{\text{FISH}} \geq 6$: Positive. For the MTP analysis, the 25 cases were grouped into 5 batches and samples were processed sequentially in one run with the MTP, while one positive (IHC 3+ score) and one negative (IHC 0 score) control sample were each time included in the batch. An automated algorithm was used to determine the regions of interest with epithelial cells and remove the background, as illustrated in Fig. S5, for each tile of the mosaic image of a given sample. This resulted in one average HER2 and CK signal per tile, which is represented by a point in a scatter plot for each patient. The scatter plot shows the correlation between the tile-averaged HER2 and CK signals (blue), compared with the scatter plot data obtained from the IHC 3+ (green) and IHC 0 (red) control samples of the batch. Analysis of the scatter plots, as further illustrated in Fig. 3, provided a MTP score for each patient that clearly correlated with $N_{\text{FISH}}$ obtained from routine analysis.
(blue) from which two scored as 2+ and one as 3+ and had \( N_{\text{FISH}} \) values of 1.9, 4.4, and 9.4, respectively. In our data processing algorithm, the ratio between HER2 and CK signals was obtained on a tile-by-tile basis from the scatter plot data of Fig. 2. The thus obtained population is plotted as a histogram, indicating the frequency of occurrence of a particular ratio; this frequency is normalized by the number of tiles for the given case. A Gaussian fit to the histogram allowed determining the mean HER2/CK value, which was normalized by the mean of the 3+ control sample in the batch, defining the M-score. Similarly, the standard deviation (σ) of the Gaussian fit, normalized by σ of the 3+ control sample, defined the \( \Sigma \)-score. The MTP-score is defined as the product of the M- and \( \Sigma \)-scores.

Figure 3. Automated comparison of a scatter plot to those of control cases. Routine analysis prior resulted in the following IHC scores: one 3+ case (green), one 0 case (red), and three borderline cases (blue), the latter having \( N_{\text{FISH}} \) of 1.9, 4.4, and 9.4, respectively. In our data processing algorithm, the ratio between HER2 and CK signals was obtained on a tile-by-tile basis from the scatter plot data of Fig. 2. The thus obtained population is plotted as a histogram, indicating the frequency of occurrence of a particular ratio; this frequency is normalized by the number of tiles for the given case. A Gaussian fit to the histogram allowed determining the mean HER2/CK value, which was normalized by the mean of the 3+ control sample in the batch, defining the M-score. Similarly, the standard deviation (σ) of the Gaussian fit, normalized by σ of the 3+ control sample, defined the \( \Sigma \)-score. The MTP-score is defined as the product of the M- and \( \Sigma \)-scores.

Moreover, in an effort to explore the advantages of short incubation times for accurate IHC independent of the image analysis protocol, we have done additional experiments on tissue samples, in which we specifically used an off-chip protocol with long incubation times (typically 1 hour) for the staining, after which IF was assessed using the same automatic image analysis protocol. Figure S2A shows the histograms of the HER2/CK ratio for a few cases, either obtained with (i) the MTP using short incubation times, or (ii) the off-chip protocol using 1 hour incubation. We clearly observe that the histograms become broader and shift to higher HER2/CK ratios, especially for \( N_{\text{FISH}} < 6 \), which is the interval for which equivocal results are encountered.
MTP fine-tunes immunoreactions and produces an IF staining that is linearly proportional to the Ag concentration on the tumor cell surface. In order to better understand the origins of the precision in the obtained IF staining that can even be used to estimate the gene copy number, we performed a proof-of-concept experiment by immobilizing fluorescently labeled Ags on a glass surface with various volume concentrations, which ranged from 0 to 1000 μg/mL. As depicted in Fig. 5, long incubation times of one hour for manual assays resulted in a non-linear relationship between the Ab fluorescent signal and its Ag, showing sudden Ab signal saturation with respect to its Ag concentration. On the contrary, when the incubation time for the Ab-Ag reaction was limited to 2 minutes and the MTP was used for the staining, we observed a signal from the antibodies that was more proportional to that of the Ags. The linear fit of the Ab-Ag signal plotted in Fig. 5F resulted in a regression coefficient of 0.96. This experiment was performed using fluorescently labeled IgG and showed the advantage of using precise microfluidic IF to significantly reduce the incubation times when compared to current standard protocols that use incubation times from 30 minutes to a few hours. Even though the characteristics of the IgG spotting experiments do not fully correspond to those of the tissue, the recognition process is also based on an Ag-Ab interaction at a surface, like on a tissue slide. The implementation of a spotting microarray allowed us to obtain a direct fluorescence signal from the Ags and compare it to the signal from the recognizing Abs in an analytical fashion. On top of this, this assay allowed us to create a controlled gradient of Ag concentrations on the same slide, which is not possible with tissue sections. Finally, we performed a second incubation with antibodies that recognized the previously incubated IgGs. The results (not shown in this plot) also manifested that a short incubation time of 2 minutes gives a signal that is more proportional to the Ag concentration than an incubation of one hour.

Discussion

Microfluidic precision IF proved to be very powerful in terms of quantifying Ag expression in histopathological tissue sections, significantly increasing the precision of the information that can be obtained by an immunoassay. Experiments showed that HER2 biomarker quantification, as obtained by the presented method, can provide molecular information that is as precise as data obtained by FISH tests, while keeping the cost and time advantage of an IF assay. We showed that the low incubation times (<8 minutes) allowed by microfluidic staining resulted in a proportional relationship between the IF signal and the corresponding Ag concentration, and that this feature was lost when using higher incubation times, which basically explained the basis of the precision in the results. The linearity of the staining, combined with low-complexity image analysis, allowed us to establish a continuous scoring that linearly followed the gene copy number as assessed by in situ hybridization.

Today, ISH is used as a gold standard for HER2 gene amplification assessment in breast cancer and for other diagnostic applications, and is replaced to some extent by conventional IHC as a surrogate marker of the genetic status. While this first proof-of-concept comparison of the presented method against FISH results is already promising, showing that the same results can be obtained much faster and at a lower cost, the microfluidic precision IF method used to obtain the scatter plots hereby presented has potentially a higher degree of clinical relevance.

FISH assessment is done by averaging the HER2 gene copy number and the HER2/CEP17 ratio of 20 to over 100 nuclei of invasive cancer cells, though intra-tumoral genetic heterogeneity is a well-known phenomenon and a challenge for HER2 evaluation in some breast cancer cases. 2013 ASCO/CAP guidelines have partially clarified this point and stressed the importance of screening the whole section to detect heterogeneous, (partially) amplified cases.
Interestingly, for cases 6, 9 and 14 in this study, heterogeneity was detected by both technical approaches. Routine IHC followed by FISH analysis demonstrated two areas of the tissue expressing/amplifying HER2 at different levels. On the other hand the scatter plots obtained (see Fig. 2) using our method showed that there are 2 distinct populations with different levels of HER2 expression, in comparison to a negative NFISH.

What is more, we do know that gene copy number gain is not always sufficient for protein overexpression. The scatter plot of case 15, having an $N_{\text{FISH}}$ value of 4.9, correlates more with the HER2-negative control signature with MTP-scores less than 0.1, suggesting that although there is a moderate copy number gain, there is no significant protein overexpression. Indeed, case 15 was considered equivocal/positive by FISH analysis, even though the IHC score was +1 (see Table S1).

Further clinical studies comparing the MTP score to clinical outcomes (such as survival and response to anti-HER2 targeted therapies) are required to show if the MTP score can be used to more precisely predict the treatment success in clinical assessment of HER2. In addition to the HER2 biomarker case presented here, another example is anaplastic lymphoma kinase (ALK) biomarker searched in non-small cell lung cancer, where ALK gene rearrangements assessed by FISH is used to define a positive ALK status. However, the response rate to targeted therapy (Crizotinib) remains around 58% for ALK-positive patients diagnosed this way. While ALK protein expression as detected by IHC is progressively being introduced as a surrogate marker for ALK gene rearrangement, one immediate further validation of our approach could involve the quantitative evaluation.
of ALK expression in non-small cell lung cancers. Finally, the scatter signature and MTP score obtained by precision microfluidic IF can increase the correlation between the biomarker assessment and treatment response, by establishing the missing link between gene status assessment by FISH and protein expression evaluation by IHC.

To conclude, we anticipate that the clinical implication of the presented results is potentially more significant than a mere application of the presented method in eliminating complementary ISH assessment in HER2 expression or other biomarkers. The experiments showing a more linearly proportional IF staining with respect to the Ag expression level, combined with the obtained scatter plots, imply that standard IHC is potentially masking some clinically relevant protein biomarker information. The expansion of this technique and the integration of the obtained information to routine diagnostic workflows may imply a major leap towards the concretization of precision medicine. Microfluidic precision IF uses standard sample preparation techniques and clinically validated primary antibodies. As digital pathology slide scanners are becoming more and more common, a switch to IF scanning would be easier, and does not imply high testing costs as opposed to complementary genetic testing practices like ISH. A low-complexity algorithm, as presented here, can easily generate scatter plots and a score without requiring too much computational power. Such quantitative data can be used as a scoring aid to pathologists, to increase success of treatment response prediction and prognosis. In the future, larger clinical studies for several markers will be required to further validate and prove the impact of microfluidic precision IF technology in cancer diagnosis.

**Methods**

**Study design.** This pilot study tested the ability to quantitatively score the level of overexpression of the HER2 protein in breast carcinoma samples using the MTP and compare it with the \( N_{\text{ISH}} \) value and the HER2/CEP17 ratio provided by routine diagnostic. Patient samples were obtained from the Institute of Pathology, Centre Hospitalier Universitaire Vaudois (CHUV), Université de Lausanne (UNIL), Lausanne, Switzerland. Twenty-five samples from patients were carefully selected to span across a wide range of \( N_{\text{ISH}} \) values, assessed at the Institute of Pathology according to 2013 ASCO recommendations. For the MTP analysis, the 25 cases were grouped into 5 batches that were processed sequentially. One positive (IHC 3+ score) and one negative (IHC 0 score) control sample was each time included in the batch. The study has been conducted on anonymized tissues of subjects that have not expressed any objection to the use of their tissue, in accordance with the recommendations and after validation by the Ethical Commission of Clinical Research of the state of Vaud (BB51/2012).

**Tissue preparation and reagents.** Breast carcinoma samples were obtained from the bio-bank of the Institute of Pathology and provided as 4\( \mu \)m FFPE sections mounted on Super Frost Plus slides (Menzel-Glaser, Germany). Tissue samples were first dehydrated for 10 min at 65 °C, then dewaxed using Histo-clear (National Diagnostics, GA, USA) for 10 min and rapidly rehydrated using ethanol solutions in decreasing concentrations (100%, 95%, 70% and 40% vol/vol) (Sigma-Aldrich, MO, USA). Subsequently, heat-induced Ag retrieval was done using sodium citrate buffer pH 6 (code: S1699 Dako, Denmark) for 10 min at 95 °C in a hot bath. The samples were then cooled down to room temperature for 20 min and immersed in phosphate buffered saline pH 7.4 (PBS) (Sigma Aldrich, MO, USA). The histological slides were inserted into the device to run the MTP staining assay. PBS was used as a buffer for cleaning and priming of the fluidic path. Double-staining was performed using rabbit anti-human c-erbB-2 oncoprotein (code: A0485, Dako, Denmark) and mouse anti-human cytokeratin, clone AE1/AE3 (code M3515, Dako, Denmark), as primary antibodies, with a concentration of 1.28 and 10.02 μg/mL, respectively. For fluorescent detection, Alexa Fluor 594 goat anti-rabbit IgG (H + L) (code: A-11037, Life Technologies, CA, USA) and Alexa Fluor 647 goat anti-mouse IgG (H + L) (code: A-21236, Life Technologies, CA, USA) secondary antibodies, at a concentration of 50 μg/mL, were employed. Nuclear counterstaining was realized using DAPI, included in Fluoroshield (code: F6057, Sigma Aldrich, MO, USA) mounting solution. All the anti-bodies were dissolved in a 0.05% (vol/vol) solution of Tween 20 (code: P137-9, Sigma Aldrich, MO, USA) in PBS.

**Routine analysis.** For routine determination of HER2 status of breast cancer cases at the Institute of Pathology, IHC was performed on 4\( \mu \)m FFPE sections on the Ventana Benchmark automat (Ventana Medical Systems, AZ, USA). The samples were stained using Ventana anti-HER2/new Ab (clone: 4B5) and scored according to current ASCO/CAP guidelines. FISH was done manually on 4\( \mu \)m FFPE sections using the PathVysion HER-2 DNA probe kit (Abbott Molecular, IL, USA). Signal analysis was performed on a minimum of 40 nuclei per case after screening of the whole section.

**Device fabrication and experimental setup.** The MTP was designed using Virtuoso (Cadence, CA, USA) and then fabricated via deep reactive ion etching of microfluidic channels on a silicon substrate, followed by bonding of a Parylene C-coated Pyrex wafer (Fig. S3 of the Supplementary Information), thereby forming 100-\( \mu \)m high and 250-\( \mu \)m wide microfluidic channels. The details of this fabrication technique can be found elsewhere. The MTP formed a fluidic halve-chamber that was reversibly clamped with a tissue slide using the force provided by a permanent magnet (Fig. S4). When forming the MTP-glass slide fluidic chamber, the histological glass slide was clamped against the MTP via a polydimethylsiloxane gasket, both to fix the height of the reaction chamber to 100 \( \mu \)m and to prevent leakage. For interfacing the MTP with external fluidic control systems, a polymethylmethacrylate holder is assembled with the MTP. Fluid manipulation was realized using five syringe pumps (Cetoni, Germany) that were filled with the required reagents and connected to the inlet of the MTP via the holder (Fig. S4).

**MTP IF staining protocol.** After clamping the MTP with the glass slide, the staining protocol lasted 10 minutes and is detailed in Table S2. PBS solution, used to wash the chamber in between steps, was delivered at 2.5 \( \mu \)L/s for 10 seconds. Ab solutions were delivered at 10 \( \mu \)L/s for 12 seconds, and incubated for 2 minutes with a slow flow
of 20 nL/s. Upon finalization of the staining protocol, the tissue samples were washed off-chip with deionized water for ten seconds and mounted using 170-μm coverslip using a DAPI-containing solution. For our experimental design related to the incubation time, we considered the typical values of IgG Ag-Ab binding constants $k_{on}$ ($\sim 10^{-7}-10^{-9}$ M$^{-1}$s$^{-1}$) and $k_{off}$ ($\sim 10^{-3}$ s$^{-1}$) in the bulk Ab concentration $c_{bulk}$ ($\sim 10^{-4}$ M) was chosen large enough so that it is not a limiting factor for the Ab surface coverage and the IF signal in a Langmuir isotherm hypothesis. The binding constants allow to calculate the desorption time $t_d = 1/k_{off} \sim 10^3$s, while the time constant of the recognition reaction is $\tau = 1/(k_{on}c_{bulk} + k_{off}) \sim 10^{-2}$ s. This forms the basis for our choice of a few minute incubation times.

**Fluorescence image acquisition.** Slides were inserted in an automated epi-fluorescent microscope (Axio Imager M2m, Zeiss, Germany) and mosaic images were obtained using a CCD camera. Images in three fluorescent channels, corresponding to the signals of DAPI, CK and HER2, respectively, were automatically obtained. Autofocusing, acquisition, scanning and stitching were done automatically. Prior to analysis, all images were checked if they contained artifacts that could influence the analysis. Based on this assessment, cases 22 and 25 were removed from the dataset due to the lack of epithelial cells in the stained slide that eventually resulted in a Gaussian fit with a low adjusted $R^2$ value of 0.4837 and 0.4806, respectively. This was already evident from the scatter plot in Fig. 2 that indicated a lack of tiles for that case. The average image acquisition varies from 10 to 40 minutes, depending on the size of the sample.

**Determination of the regions of interest for interrogation of the HER2 signal.** HER2 protein is situated on epithelial cell membranes. We performed double-staining IF assays using CK as a second marker in addition to the HER2 analysis, due to its expression in all epithelial cells, so that the information on the CK channel could be used to define the areas where the expression of HER2 should be interrogated. ImageJ macros were applied tile-by-tile (n = 40482). To do this, we built an auto-thresholding algorithm that determines where CK is expressed to define the region of interest. Similarly, the information in the DAPI channel was used to identify the nuclei as areas that should not be interrogated, as HER2 does not constitute a nuclear marker. In HER2-overexpressing samples (Fig. S5A), the use of HER2 signal alone would be clearly sufficient to determine the regions of interest; for tumors that do not strongly overexpress HER2 (Fig. S5B), it would be difficult to distinguish epithelial cells from surrounding parts in the tissue. Especially in these cases, employing the signal in the CK channel allowed us to assure that the regions of interest for interrogation of the HER2 signal corresponded to epithelial cells, independent from the intensity of the HER2 signal. As a result of this procedure, every tile was assigned an average signal value both for CK and HER2. The thus obtained CK signal intensities were analyzed and filtered, in a case-by-case fashion, in order to remove from further analysis the tiles that had none or a few epithelial cells. In particular, these tiles showed a CK average that fell below a given threshold and were automatically filtered out from the dataset (Fig. S6). Finally, de facto establishing an upper threshold of the CK signal, we removed the 5% brightest tiles for each case, to account for possible artifacts like small agglomerates of fluorophores that eventually result in saturation of the fluorescent signal intensity. All tiles that showed a CK average below the upper and below the upper thresholds were kept for further analysis. The detailed steps of the image-processing algorithm can be found in Table S3 of the Supplementary Information. OriginLab software (OriginLab Corporation, MA, USA) was used to obtain scatter plots, histograms and statistical values. The image-processing algorithm takes approximately 20 minutes per batch, giving an average of 3 minutes per sample.

**Spotting and incubation of fluorescently labeled antibodies on functionalized slides.** Fluorescently labeled AF647 mouse antibodies (code: A-21239, Life Technologies, CA, USA) were spotted on epoxy-functionalized glass slide (Super Epoxy slides, Arrayit, CA, USA) with a concentration ranging from 0 to 1000 μg/mL using a commercially available contact spotter (QArray Mini, Genetix, MA, USA). The MTP-based incubation of recognizing antibodies was done using AF488 anti-mouse antibodies (code: A-11034, Life Technologies, CA, USA), with a concentration of 50 μg/mL. ImageJ macros were used to segment the spot areas and obtain the average fluorescent signal. OriginLab software (OriginLab Corporation, MA, USA) was used to plots the results.

**References**

1. Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B. & Workman, P. Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance. *Clin. Pharmacol. Ther.* 93, 252–259 (2013).
2. Tamibieroud, A.-M. et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. *Clin. Cancer Res.* 18, 6373–6383 (2012).
3. Becker, K.-E. et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. *J. Pathol.* 211, 370–378 (2007).
4. Koh, J. et al. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. *Histopathology* 65, 808–878 (2014).
5. Wolff, A. C. et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *J. Clin. Oncol.* 31, 3997–4013 (2013).
6. Rimm, D. L. What brown cannot do for you. *Nat. Biotechnol.* 24, 914–916 (2006).
7. Carvajal-Hausdorf, D. E., Salcher, K. A., Neumeister, V. M. & Rimm, D. L. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. *Lab. Invest.* 95, 385–396 (2015).
8. Pauletti, G. et al. Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry. *J. Clin. Oncol.* 18, 3651–3664 (2000).
9. Owens, M. A., Horten, B. C. & Da Silva, M. M. HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6536 Breast Cancer Tissues. *Clin. Breast Cancer* 5, 63–69 (2004).
10. Brown, J., DeCerenna, M., Källén, B., Lannin, D., Rimm, D. L. & Rimm, D. L. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. *Lab. Invest.* 94, 98–106 (2014).
11. McCabe, A., Dollefil-Filhart, M., Camp, R. L. & Rimm, D. L. Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis. *JNCI J. Natl. Cancer Inst.* 97, 1808–1815 (2005).
12. Rojo, M. G., Bueno, G. & Słodkowska, J. Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. Folia Histochem. Cytobiol. 47, (2010).
13. Caelen, I. et al. Formation of Gradients of Proteins on Surfaces with Microfluidic Networks. Langmuir 16, 9125–9130 (2000).
14. Squires, T. M., Messinger, R. J. & Manalis, S. R. Making it stick: convection, reaction and diffusion in surface-based biosensors. Nat. Biotechnol. 26, 417–426 (2008).
15. Cflik, A. T., Lehr, H.-A. & Gis, M. A. M. Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outs. Proc. Natl. Acad. Sci. 110, 5363–5368 (2013).
16. Kent, S. P., Ryan, K. H. & Siegel, A. L. Steric hindrance as a factor in the reaction of labeled antibody with cell surface antigenic determinants. J. Histochem. Cytochem. 26, 618–621 (1978).
17. Van der Loos, C. M., Das, P. K., Van den Oord, J. J. & Houthoff, H. J. Multiple immunoenzyme staining techniques use of fluorescenciated, biotinylated and unlabelled monoclonal antibodies. J. Immunol. Methods 117, 45–52 (1989).
18. Van der Loos, C. M. Multiple Immunoenzyme Staining: Methods and Visualizations for the Observation With Spectral Imaging. J. Histochem. Cytochem. 56, 313–328 (2007).
19. Lane, E. B. & Alexander, C. M. Use of keratin antibodies in tumor diagnosis. Semin. Cancer Biol. 1, 165–179 (1990).
20. Barak, V., Golke, H., Panaretakis, K. W. & Einarsson, R. Clinical utility of cytokeratins as tumor markers. Clin. Biochem. 37, 529–540 (2004).
21. Gustavsson, M. D. et al. Standardization of HER2 Immunohistochemistry in Breast Cancer by Automated Quantitative Analysis. Arch. Pathol. Lab. Med. 133, 1413–1419 (2009).
22. Kwon, S., Cho, C. H., Lee, E. S. & Park, J.-K. Automated Measurement of Multiple Cancer Biomarkers Using Quantum-Dot-Based Microfluidic Immunohistochemistry. Anal. Chem. 87, 4177–4183 (2015).
23. Hanna, W. M. et al. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod. Pathol. 27, 4–18 (2014).
24. Weickhardt, A. J. et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer: Diagnostic Assays for ALK in NSCLC. Cancer 119, 1467–1477 (2013).
25. Shaw, A. T. et al. Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer. N. Engl. J. Med. 370, 1189–1197 (2014).
26. Boland, J. M. et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas. Hum. Pathol. 40, 1152–1158 (2009).
27. Selinger, C. I. et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 26, 1545–1553 (2013).
28. Cflik, A. T. & Gis, M. A. M. A low-temperature parylene-to-silicon dioxide bonding technique for high-pressure microfluidics. J. Micromechanics Microengineering 21, 035011 (2011).
29. Cflik, A. T. & Gis, M. A. M. Parylene to silicon nitride bonding for post-integration of high pressure microfluidics to CMOS devices. Lab. Chip 12, 396 (2012).
30. Janin, J. The kinetics of protein-protein recognition. Proteins Struct. Funct. Genet. 28, 153–161 (1997).
31. Bongrand, P. Ligand-receptor interactions. Rep. Prog. Phys. 62, 921–968 (1999).

Acknowledgements
We thank A. Sayah from the Laboratory of Microsystems for the technical discussions, S. Leuba from the Institute of Pathology for collecting and preparing the samples for this study, and Prof. M. Lutolf and S. Gobaa for granting access to their spotting facilities. D.G.D is supported by the National Competence Center for Biomedical Imaging (NCCBI.ch), A.T.C and D.H. were partially supported by the Swiss Commission of Technology and Innovation (CTI) under grant number 15611.1 PFLS-LS and partially by Lunaphore Technologies SA.

Author Contributions
D.G.D., A.T.C. and M.A.M.G. designed and fabricated the microfluidic device and the experimental setup; A.T.C., D.G.D., M.A.M.G. and M.F. designed the clinical study; D.G.D. and D.H. ran the microfluidic experiments and the image acquisition; D.G.D. performed the image processing and data analysis, M.F. and B.B. performed the routine analysis of the samples, D.G.D., A.T.C. and M.A.M.G. analyzed the results. M.A.M.G. and L.d.L. supervised the study; D.G.D. and M.A.M.G. wrote the paper; all authors corrected it.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: A.T.C. and D.H., at the submission of the paper, are employed at Lunaphore Technologies SA, which is commercializing the MTP-based technology. Some of the authors have equity interest in Lunaphore Technologies SA.

How to cite this article: Dupouy, D. G. et al. Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer. Sci. Rep. 6, 20277; doi: 10.1038/srep20277 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/